Mie K Eickhoff1, Flemming J Olsen2, Marie Frimodt-Møller1, Lars J Diaz1, Jens Faber3, Magnus T Jensen2, Peter Rossing4, Frederik Persson5. 1. Steno Diabetes Center Copenhagen, Denmark. 2. Herlev Gentofte Hospital, Department of Cardiology, Denmark. 3. Herlev Gentofte Hospital, Department of Endocrinology, Denmark. 4. Steno Diabetes Center Copenhagen, Denmark; University of Copenhagen, Department of Clinical Medicine, Denmark. 5. Steno Diabetes Center Copenhagen, Denmark. Electronic address: Frederik.persson@regionh.dk.
Abstract
AIMS: Sodium glucose transport inhibitors (SGLT2i) can reduce risk of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and existing cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac function in people with T2D and albuminuria. METHODS: A secondary analysis of a double-blind, randomized, cross-over study of 12 weeks treatment with dapagliflozin 10 mg versus placebo. Myocardial function was assessed by echocardiography and biomarkers of cardiac risk were measured. An exploratory diastolic composite of echocardiographic variables was computed. RESULTS: Of the 36 participants completing the study 89% were male, mean age 64 ± 8 years, diabetes duration 16.4 ± 4.7 years and HbA1c 73 ± 15 mmol/mol (8.9 ± 1.4%), 30.6% had former cardiovascular events and 32% had macroalbuminuria. Mean left ventricular ejection fraction (LVEF) was 55.4% after placebo and 54.3% after dapagliflozin (p = 0.15), global longitudinal strain -16.1 vs. -15.9, (p = 0.64), E/e' 7.6 vs. 7.6 (p = 0.082), and tissue Doppler velocity e' 10.0 vs. 10.6 (p = 0.05). The composite score showed diastolic function improvement of 19.8% (p = 0.021). No other significant changes were observed. CONCLUSIONS: Dapagliflozin may have minor effects on diastolic function in people with T2D, albuminuria and preserved LVEF.
RCT Entities:
AIMS: Sodium glucose transport inhibitors (SGLT2i) can reduce risk of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and existing cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac function in people with T2D and albuminuria. METHODS: A secondary analysis of a double-blind, randomized, cross-over study of 12 weeks treatment with dapagliflozin 10 mg versus placebo. Myocardial function was assessed by echocardiography and biomarkers of cardiac risk were measured. An exploratory diastolic composite of echocardiographic variables was computed. RESULTS: Of the 36 participants completing the study 89% were male, mean age 64 ± 8 years, diabetes duration 16.4 ± 4.7 years and HbA1c 73 ± 15 mmol/mol (8.9 ± 1.4%), 30.6% had former cardiovascular events and 32% had macroalbuminuria. Mean left ventricular ejection fraction (LVEF) was 55.4% after placebo and 54.3% after dapagliflozin (p = 0.15), global longitudinal strain -16.1 vs. -15.9, (p = 0.64), E/e' 7.6 vs. 7.6 (p = 0.082), and tissue Doppler velocity e' 10.0 vs. 10.6 (p = 0.05). The composite score showed diastolic function improvement of 19.8% (p = 0.021). No other significant changes were observed. CONCLUSIONS:Dapagliflozin may have minor effects on diastolic function in people with T2D, albuminuria and preserved LVEF.
Authors: Viktor Rotbain Curovic; Morten B Houlind; Tine W Hansen; Jesper Eugen-Olsen; Jens Christian Laursen; Mie K Eickhoff; Frederik Persson; Peter Rossing Journal: Front Pharmacol Date: 2022-04-27 Impact factor: 5.810
Authors: Caitlin Fern Wee; Yao Hao Teo; Yao Neng Teo; Nicholas Lx Syn; Ray Meng See; Shariel Leong; Alicia Swee Yan Yip; Zhi Xian Ong; Chi-Hang Lee; Mark Yan-Yee Chan; Kian-Keong Poh; Ching-Ching Ong; Lynette Ls Teo; Devinder Singh; Benjamin Yq Tan; Leonard Ll Yeo; William Kf Kong; Tiong-Cheng Yeo; Raymond Cc Wong; Ping Chai; Ching-Hui Sia Journal: J Cardiovasc Imaging Date: 2022-07